FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 8, 2026 47 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POTOMAC study Source RELATED ARTICLESMORE FROM AUTHOR Benefit of Adjuvant Chemotherapy in Patients with ctDNA-positive Resected Stage II Colon Cancer FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC Peptide Receptor Radionuclide Therapy [177Lu]Lu-Edotreotide Prolongs PFS in Patients with Advanced, Progressive, Somatostatin Receptor-Positive GEP NETs MOST POPULAR Firefighter Advocates For Men’s Health While He Battles Breast Cancer In... September 22, 2021 Persistent Poverty Linked to Increased Risk of Dying from Cancer November 19, 2020 Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell... July 15, 2025 The RAD51-IF Test Is Feasible for Assessment of the Functional Status... May 7, 2021 Load more HOT NEWS Efficacy of a Bispecific Monoclonal Antibody Glofitamab for Relapsed or Refractory... FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell... 9-Year-Old Has His Final Cancer Treatment After 3 Years – Breaks... New Research Looks for More Effective Breast Cancer Treatments for Black...
